Skip to main content
Cybin Inc. logo

Cybin Inc. — Investor Relations & Filings

Ticker · HELP NEO Manufacturing
Open in API
Filings indexed 441 across all filing types
Latest filing 2025-05-01 Regulatory Filings
Country CA Canada
Listing NEO HELP

About Cybin Inc.

http://www.cybin.com

Cybin Inc. is a clinical-stage biopharmaceutical company specializing in breakthrough neuropsychiatry, committed to developing next-generation therapeutics to revolutionize mental healthcare. The company utilizes proprietary drug discovery platforms to innovate Novel Serotonergic Agonists (NSAs)—synthetic molecules designed to activate serotonin pathways and promote neuroplasticity—paired with precision drug delivery systems. A core technological differentiator is the use of deuteration technology to create treatments with consistent delivery and commercial scalability. Cybin maintains a robust intellectual property portfolio, including over 100 granted patents and 250 pending applications, supporting its active drug programs, such as CYB004, currently in Phase 2 clinical trials for the treatment of Generalized Anxiety Disorder. The mission is to provide treatments designed to foster durable improvements in mental health.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing the CEO’s participation in an upcoming conference panel. It is not an earnings release, financial report, management change, proxy statement, share transaction, or any other specific category. It does not contain financial results, governance details, or capital-raising information, nor is it announcing publication of a report. Therefore it falls into the fallback category for miscellaneous regulatory announcements: RNS.
2025-05-01 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Business Wire press release announcing clinical site partnerships for Cybin’s Phase 3 program. It contains forward-looking statements, company overview, and contact information, but it is not an earnings release, financing notice, management change, or any formal regulatory submission. It does not attach or publish a report, nor does it fall under any specialized category. Therefore, it is classified as a general regulatory/fallback announcement.
2025-04-23 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a Business Wire press release announcing a strategic partnership between Cybin and Osmind to prepare for commercialization of clinical-stage programs. It is not an annual or interim report, earnings release, financing update, M&A, or management change. There is no mention of financial results or regulatory filings like 10-K, IR, or AR, nor is it a publication announcement of a separate report. Therefore, it falls under the general 'Regulatory Filings' fallback category.
2025-04-21 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release on Business Wire reporting unaudited financial results for the third quarter ended December 31, 2024, along with key operational and clinical program highlights. It provides headline metrics (net loss, cash position, operating expenses) and recent business developments rather than the full interim financial statements. This format and content correspond to an Earnings Release (ER). Q3 2025
2025-02-11 English
Prospectus (non pricing) supplement (ATM) – English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a prospectus supplement and base shelf prospectus qualifying an equity offering of up to US$100 million of common shares. It details the plan of distribution, use of proceeds, risk factors, and other offering terms. This is a formal announcement of a new share issuance, matching the definition for Share Issue/Capital Change (Code: SHA).
2025-02-11 English
Other material contract(s).pdf
Capital/Financing Update Classification · 1% confidence The document is an Equity Distribution Agreement between Cybin Inc. and Cantor Fitzgerald, outlining the terms under which the company may issue and sell shares (up to US$100 million) via an at-the-market program. It is a contractual agreement detailing a financing arrangement, not an earnings release, management change, or annual report. This clearly falls under updates on company fundraising and capital structure changes. Therefore, the correct classification is Capital/Financing Update (CAP).
2025-02-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.